



SurModics IVD Breakthrough Stabilizer Addresses Industry Challenge

July 29, 2013

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jul. 29, 2013-- SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for [in vitro diagnostic assay components](#), is launching its new [StabilZyme® Protein-Free Stabilizer](#) today at the American Association for Clinical Chemistry (AACC) meeting in Houston.

“This newest addition to SurModics’ stabilization line is significant for assay developers because it helps even their most sensitive assays function optimally,” says Gary Maharaj, CEO and president. “Assay developers have been asking for a top performing, protein-free stabilizer that addresses their growing needs in the areas of sensitivity, specificity and reliability.”

Assays have become increasingly sensitive in recent years. However, the protein stabilizers most commonly used to stabilize biomolecule activity may contribute to interference and cross-reactivity. SurModics’ new *StabilZyme* Protein-Free Stabilizer delivers excellent retained activity—a key performance factor—while eliminating the risk of interference and cross-reactivity.

SurModics IVD offers a full range of innovative solutions, including custom formulations, for the *in vitro* diagnostics industry. To learn more, please visit us at AACC (Booth No. 1434), visit our website (www.surmodics.com), or contact customer service (952-500-7200 or orders@surmodics.com). More than 900 IVD products are available for online ordering at <http://shop.surmodics.com>. *SurModics* and *StabilZyme* are registered trademarks of SurModics, Inc.

About SurModics, Inc.

SurModics’ mission is to exceed our customers’ expectations and enhance the wellbeing of patients by providing the world’s foremost, innovative surface modification technologies and *in vitro* diagnostic chemical components. The Company partners with the world’s leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include (i) surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities, and (ii) components for *in vitro* diagnostic tests and microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit <http://www.surmodics.com>. The content of SurModics’ website is not part of this release or part of any filings the Company makes with the SEC.

Source: SurModics, Inc.

SurModics, Inc.

Andy LaFrance, 952-500-7000

Vice President Finance and Chief Financial Officer